Reply to: Technical challenges of studying the impact of plasma components on the efficacy of lipid nanoparticles for vaccine and therapeutic applications.

Liu, Kai; Lázaro-Ibáñez, Elisa; Lerche, Michael; Lindén, Daniel; Salvati, Anna; Sabirsh, Alan

Liu, Kai; Lázaro-Ibáñez, Elisa; Lerche, Michael; Lindén, Daniel; Salvati, Anna; Sabirsh, Alan.

Afiliação

Liu K; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Lázaro-Ibáñez E; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Lerche M; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Lindén D; Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Salvati A; Division of Endocrinology, Department of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Sabirsh A; Department of Nanomedicine & Drug Targeting, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, 9713AV, The Netherlands.

Nat Commun ; 15(1): 3853, 2024 May 09.

Article em En | MEDLINE | ID: mdl-38724506

Assuntos

Lipídeos; Nanopartículas; Nanopartículas/química; Humanos; Lipídeos/química; Plasma/química; Lipossomos; Vacinas/administração & dosagem; Vacinas/imunologia; Animais

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nanopartículas / Lipídeos Limite: Animals / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google